Siddharth Bhargava, MD
Ophthalmology · Upland, CANPI 1043849078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,344 of the $3,654 with a category attached, or 64.1%. AbbVie accounts for 61.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,540 and has fallen 76.7% since, to $592 in 2025.
Across 39 payments — averaging $93.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sight Sciences, Inc.$740
- NEW World Medical,inc.$336
- Biotissue Holdings Inc.$148
- AstraZeneca$69
- Harrow Eye, LLC$36
- plus $68 from 3 others
What the payments were for
- Travel & lodging$1,21033%
- Food & beverage$2,34464%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $2,256 |
| Sight Sciences, Inc. | 9 | $740 |
| NEW World Medical,inc. | 3 | $336 |
| Biotissue Holdings Inc. | 3 | $148 |
| AstraZeneca | 1 | $69 |
| Harrow Eye, LLC | 1 | $36 |
| Thea Pharma Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Alcon | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$1,405
- OMNI(R) SURGICAL SYSTEM (US)$541
- Kahook Dual Blade$336
- Clearpath$336
- Ahmed Glaucoma Valve$336
- Streamline$336
- SION SURGICAL INSTRUMENT$270
- LUMIGAN$124
- DURYSTA$120
- Via360$107
How this compares
$3,654 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 46 | $1,263 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $687 |
| Latanoprost | 67 | $482 |
| MoxifloxacinMoxifloxacin Hcl | 19 | $405 |
| Brimonidine Tartrate | 50 | $309 |
| Ketorolac Tromethamine | 14 | $244 |
| Dorzolamide Hcl | 16 | $232 |
| Timolol Maleate | 14 | $131 |
| Ofloxacin | 11 | $115 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Upland
- Edward YungUpland$165K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.